S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

IGM Biosciences (IGMS) Stock Forecast, Price & News

+0.74 (+4.41%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
498,204 shs
Average Volume
391,560 shs
Market Capitalization
$744.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IGMS News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGM Biosciences logo

About IGM Biosciences

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$4.81 per share


Net Income
$-165.16 million
Pretax Margin




Free Float
Market Cap
$744.70 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.28 out of 5 stars

Medical Sector

288th out of 1,416 stocks

Pharmaceutical Preparations Industry

108th out of 677 stocks

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

IGM Biosciences (NASDAQ:IGMS) Frequently Asked Questions

Is IGM Biosciences a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IGM Biosciences stock.
View analyst ratings for IGM Biosciences
or view top-rated stocks.

When is IGM Biosciences' next earnings date?

IGM Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for IGM Biosciences

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) announced its quarterly earnings data on Tuesday, March, 29th. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.58) by $0.08. During the same period in the prior year, the business posted ($0.79) EPS.
View IGM Biosciences' earnings history

What price target have analysts set for IGMS?

8 Wall Street analysts have issued twelve-month price targets for IGM Biosciences' stock. Their forecasts range from $30.00 to $126.00. On average, they anticipate IGM Biosciences' stock price to reach $62.56 in the next year. This suggests a possible upside of 257.3% from the stock's current price.
View analysts' price targets for IGM Biosciences
or view top-rated stocks among Wall Street analysts.

Who are IGM Biosciences' key executives?
IGM Biosciences' management team includes the following people:
  • Mr. Fred M. Schwarzer J.D., CEO, Pres & Director (Age 69, Pay $847.52k)
  • Dr. Bruce A. Keyt, Chief Scientific Officer (Age 69, Pay $636.33k) (LinkedIn Profile)
  • Dr. Shinyu Chen M.D., Ph.D., Consultant (Age 53, Pay $675.25k)
  • Mr. Misbah Tahir, Chief Financial Officer (Age 47)
  • Mr. Paul C. Graffagnino, VP of Legal Affairs
  • Ms. Suzette Tauber, Chief HR Officer (Age 58)
  • Dr. Angus M. Sinclair Ph.D., Sr. VP of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D., Chief Bus. Officer (Age 53)
  • Mr. George A. Gauthier, Chief Commercial Officer (Age 50)
  • Mr. Marvin S. Peterson Ph.D., Sr. VP of Process Devel. & Manufacturing
What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Artal Group S.A. (4.86%), Vanguard Group Inc. (2.02%), BlackRock Inc. (1.69%), Goldman Sachs Group Inc. (1.04%), State Street Corp (0.42%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own IGM Biosciences stock include Bruce Keyt, Daniel Shinyu Chen, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Redmile Group, Llc.
View institutional ownership trends for IGM Biosciences

Which major investors are selling IGM Biosciences stock?

IGMS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Citigroup Inc., Victory Capital Management Inc., TD Asset Management Inc., Group One Trading L.P., Dimensional Fund Advisors LP, and Royal Bank of Canada. Company insiders that have sold IGM Biosciences company stock in the last year include Bruce Keyt, Daniel Shinyu Chen, and Julie Hambleton.
View insider buying and selling activity for IGM Biosciences
or view top insider-selling stocks.

Which major investors are buying IGM Biosciences stock?

IGMS stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Vanguard Group Inc., HAP Trading LLC, Renaissance Technologies LLC, Charles Schwab Investment Management Inc., Cutler Group LP, GSA Capital Partners LLP, and Goldman Sachs Group Inc.. Company insiders that have bought IGM Biosciences stock in the last two years include Jakob Haldor Topsoe, M Kathleen Behrens, Michael D Loberg, and Redmile Group, Llc.
View insider buying and selling activity for IGM Biosciences
or or view top insider-buying stocks.

How do I buy shares of IGM Biosciences?

Shares of IGMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $17.51.

How much money does IGM Biosciences make?

IGM Biosciences has a market capitalization of $744.70 million. The company earns $-165.16 million in net income (profit) each year or ($5.51) on an earnings per share basis.

How many employees does IGM Biosciences have?

IGM Biosciences employs 192 workers across the globe.

What is IGM Biosciences' official website?

The official website for IGM Biosciences is igmbio.com.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-965-7873.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.